ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Endocrinology, Diabetes Metabolism

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

12,970Medicare Part D Prescriptions Filled, Including Refills

Rank: 6 out of 463

$725K Total Retail Price of All Prescriptions

Rank: 36 out of 463

409 Patients Receiving at Least One Drug in Part D
75%Patients 65 Years and Older
95% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New York
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

2% of this provider’s 10,644 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

29% of this provider’s prescriptions were for brand-name drugs, compared to an average of 49%.

Prescription Price

$56 was the average price of a prescription from this provider, compared to $131 among peers.

Prescriptions per Patient

32 is the average number of prescriptions (including refills) per patient, compared to an average of 11.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New York
SIMVASTATIN 1,107 921 1 7
METFORMIN HCL 715 606 2 3
LISINOPRIL 666 562 3 15
ATENOLOL 647 596 4 29
AMLODIPINE BESYLATE 607 483 5 12
HYDROCHLOROTHIAZIDE 385 329 6 26
METOPROLOL TARTRATE 370 316 7 31
JANUVIA 370 321 7 6
FOSINOPRIL SODIUM 301 283 9 121
NIFEDIPINE ER 300 271 10 72
LOSARTAN POTASSIUM 300 243 10 20
LEVOTHYROXINE SODIUM 235 165 12 1
OMEPRAZOLE 235 160 12 27
ALENDRONATE SODIUM 230 211 14 22
NEXIUM 223 138 15 37
GABAPENTIN 214 177 16 48
FUROSEMIDE 195 159 17 25
CRESTOR 194 170 18 13
GLYBURIDE 157 133 R 19 41
SINGULAIR 151 91 20 84
VENTOLIN HFA 146 93 21 119
AMMONIUM LACTATE 145 137 22 87
RANITIDINE HCL 145 124 22 107
ISOSORBIDE MONONITRATE ER 135 105 24 105
SINGLE USE SWAB 130 100 25 58
LANTUS 127 107 26 16
TAMSULOSIN HCL 127 106 26 67
ALCOHOL SWABS 123 89 28 57
QVAR 111 98 29 198
FLOVENT HFA 107 73 30 205
PROAIR HFA 104 70 31 138
ALCOHOL PREP PADS 98 83 32 108
NIFEDICAL XL 97 95 33 168
ADVAIR DISKUS 94 55 34 96
ACTOS 92 78 35 24
TRAMADOL HCL 84 44 36 85
CLOPIDOGREL 82 76 37 64
METOPROLOL SUCCINATE 81 73 38 28
PRANDIN 78 72 39 32
ENALAPRIL MALEATE 76 55 40 35
FLUTICASONE PROPIONATE 75 52 41 129
INSULIN SYRINGE 75 64 41 18
MONTELUKAST SODIUM 74 62 43 140
ATORVASTATIN CALCIUM 71 70 44 10
FAMOTIDINE 71 67 44 110
GLIPIZIDE 63 58 46 36
PEN NEEDLE 62 46 47 5
GLIMEPIRIDE 61 52 48 8
ALLOPURINOL 60 44 49 74
DIOVAN 59 52 50 42
HYDRALAZINE HCL 59 44 50 243
LANTUS SOLOSTAR 56 39 52 4
VOLTAREN 54 38 53 144
PLAVIX 54 49 53 61
COLCRYS 52 35 55 261
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.